S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
NASDAQ:THTX

Theratechnologies - THTX Stock Forecast, Price & News

$2.20
-0.03 (-1.35%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.90
$2.26
50-Day Range
$2.02
$2.69
52-Week Range
$1.90
$4.46
Volume
135,270 shs
Average Volume
65,366 shs
Market Capitalization
$209.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Theratechnologies MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
47.7% Upside
$3.25 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.38) to ($0.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.20 out of 5 stars

Medical Sector

979th out of 1,108 stocks

Pharmaceutical Preparations Industry

473rd out of 542 stocks

THTX stock logo

About Theratechnologies (NASDAQ:THTX) Stock

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Theratechnologies Trading Down 1.3 %

THTX Stock traded down $0.03 during mid-day trading on Wednesday, hitting $2.20. 135,270 shares of the company were exchanged, compared to its average volume of 65,366. The company has a quick ratio of 1.07, a current ratio of 1.57 and a debt-to-equity ratio of 5.38. The firm has a market capitalization of $209.27 million, a P/E ratio of -4.17 and a beta of 1.32. The business has a fifty day simple moving average of $2.29 and a 200-day simple moving average of $2.53. Theratechnologies has a 12-month low of $1.90 and a 12-month high of $4.46.

Theratechnologies (NASDAQ:THTX - Get Rating) last issued its quarterly earnings results on Thursday, July 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. The business had revenue of $19.27 million for the quarter. Theratechnologies had a negative return on equity of 474.37% and a negative net margin of 68.75%. On average, equities research analysts predict that Theratechnologies will post -0.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, National Bank Financial lowered their target price on shares of Theratechnologies from C$3.75 to C$3.25 in a research note on Friday, July 15th.

Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Stock News Headlines

Theratechnologies - Baystreet.ca
THTX Jun 2022 2.500 call
See More Headlines
Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Company Calendar

Last Earnings
7/14/2022
Today
8/11/2022
Next Earnings (Estimated)
10/12/2022
Fiscal Year End
11/30/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:THTX
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$3.25
Low Stock Price Forecast
$3.25
Forecasted Upside/Downside
+47.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-31,730,000.00
Pretax Margin
-68.50%

Debt

Sales & Book Value

Annual Sales
$69.82 million
Book Value
$0.19 per share

Miscellaneous

Free Float
N/A
Market Cap
$209.27 million
Optionable
Not Optionable
Beta
1.32

Key Executives

  • Mr. Paul Lévesque (Age 58)
    Pres, CEO & Director
    Comp: $1.24M
  • Mr. Philippe Dubuc M.B.A. (Age 55)
    MBA, Sr. VP & CFO
    Comp: $393.59k
  • Dr. Christian Marsolais Ph.D. (Age 59)
    Sr. VP & Chief Medical Officer
    Comp: $383.71k
  • Mr. John Leasure (Age 57)
    Global Commercial Officer
    Comp: $353.81k
  • Ms. Elif McDonald
    Sr. Director of Investor Relations
  • Mr. Jocelyn Lafond L.L.M. (Age 54)
    LL.B., Gen. Counsel & Corp. Sec.
  • Mr. Denis Boucher B.A. (Age 56)
    L.L.B., VP of Communications & Corp. Affairs
  • Hon. Andre Dupras (Age 58)
    VP of HR













THTX Stock - Frequently Asked Questions

What is Theratechnologies' stock price forecast for 2022?

0 equities research analysts have issued twelve-month price targets for Theratechnologies' stock. Their THTX share price forecasts range from $3.25 to $3.25. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price.
View analysts price targets for THTX
or view top-rated stocks among Wall Street analysts.

How have THTX shares performed in 2022?

Theratechnologies' stock was trading at $3.03 at the beginning of the year. Since then, THTX shares have decreased by 27.4% and is now trading at $2.20.
View the best growth stocks for 2022 here
.

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 12th 2022.
View our THTX earnings forecast
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) posted its earnings results on Thursday, July, 14th. The company reported ($0.24) earnings per share for the quarter. The business earned $19.27 million during the quarter. Theratechnologies had a negative net margin of 68.75% and a negative trailing twelve-month return on equity of 474.37%.

What guidance has Theratechnologies issued on next quarter's earnings?

Theratechnologies issued an update on its FY 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $79.00 million-$82.00 million, compared to the consensus revenue estimate of $79.55 million.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

What is Theratechnologies' stock symbol?

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Creative Financial Designs Inc. ADV (0.05%).

How do I buy shares of Theratechnologies?

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theratechnologies' stock price today?

One share of THTX stock can currently be purchased for approximately $2.20.

How much money does Theratechnologies make?

Theratechnologies (NASDAQ:THTX) has a market capitalization of $209.27 million and generates $69.82 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The official website for the company is www.theratech.com. The company can be reached via phone at (514) 336-7800, via email at communications@theratech.com, or via fax at 514-331-9691.

This page (NASDAQ:THTX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.